Cancer
Malignant Bladder Neoplasm
CI-CAN-00005866Explore in graph →
Top-level346 active trials10 approved drugs25 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005866Explore in graph →
Clinical trials
1,510 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05630131 | ctDNA in Subjects With Muscle-invasive Bladder Cancer Treated With Trimodality Therapy | completed | — | 1 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT07251946 | Development of Multiphasic CT-based Delta-Radiomics Model for Predicting Postoperative Recurrence Risk in Bladder Cancer | completed | — | 316 | Lian YangOTHER | 1 | Nov 26, 2025 |
| NCT04533672 | Multiparametric Magnetic Resonance Imaging (MRI) to Improve Bladder Cancer Staging and Treatment Decision-making(SBCT) | completed | N/A | 186 | University of ZurichOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06397040 | The Use of Remote Monitoring to Improve Patient-Reported Outcomes and Readmission Rates Following Radical Cystectomy(WATCH) | completed | N/A | 38 | University of PittsburghOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT01812369 | Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer(VESPER) | completed | Phase 3 | 500 | University Hospital, RouenOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT03914794 | A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors | completed | Phase 2 | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT06157814 | Mobile Ostomates Resources for Patients and Caregivers(MORE) | completed | N/A | 26 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT04383743 | Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer | completed | Phase 2 | 17 | University of WashingtonOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT04534075 | Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial(FIDURA) | completed | Phase 3 | 354 | Sahlgrenska University HospitalOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT06582849 | Enhanced Assistance During Radiotherapy for Unmet Essential Needs(EARN) | completed | N/A | 33 | Washington University School of MedicineOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT03232541 | The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and Vomiting | completed | N/A | 198 | Västernorrland County Council, SwedenOTHER_GOV | 1 | Aug 24, 2025 | clinicaltrials |
| NCT03039413 | Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy | completed | Early Phase 1 | 20 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT05259696 | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)(GLIMMER-01) | completed | Phase 1 / Phase 2 | 69 | Palleon Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT05111639 | Decision Making for Urinary Diversion in Patients With Bladder Cancer | completed | — | 52 | University of Colorado, DenverOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT04825834 | DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)(DELFI-L101) | completed | — | 2,992 | Delfi Diagnostics Inc.INDUSTRY | 2 | Aug 8, 2025 | clinicaltrials |
| NCT02903914 | Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors | completed | Phase 1 | 260 | Incyte CorporationINDUSTRY | 4 | Aug 5, 2025 | clinicaltrials |
| NCT04570410 | Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma | completed | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT05524545 | A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07) | completed | Phase 1 | 36 | ALX Oncology Inc.INDUSTRY | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05151341 | Study of Combined VisioCyt Test and FGFR3 Mutations on a Urinary Sample to Diagnose Bladder Tumors(URODX-FGFR3) | completed | N/A | 190 | Institut de Cancérologie de LorraineOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT02553642 | Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) | completed | Phase 2 | 81 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT06002269 | A Home-based Lifestyle Intervention for Optimizing Surgical Outcomes Among Urinary Bladder Cancer Patients(BOOST) | completed | N/A | 8 | University of UtahOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT04580485 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | completed | Phase 1 | 54 | Incyte CorporationINDUSTRY | 6 | Jul 11, 2025 | clinicaltrials |
| NCT02015104 | Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jul 1, 2025 | clinicaltrials |
| NCT03081858 | Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer | completed | Phase 1 / Phase 2 | 15 | Lipac Oncology LLCINDUSTRY | 1 | Jun 27, 2025 | clinicaltrials |
| NCT05788484 | A Study of CDX-585 in Patients With Advanced Malignancies | completed | Phase 1 | 20 | Celldex TherapeuticsINDUSTRY | 1 | Jun 15, 2025 | clinicaltrials |
| NCT05253053 | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 84 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Jun 12, 2025 | clinicaltrials |
| NCT04089748 | Basal Tumours in Bladder Cancer, Response to chemoTherapy(BoBCaT) | completed | — | 293 | University Hospital, RouenOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT04068896 | Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy | completed | Phase 1 / Phase 2 | 89 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT02844816 | Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer | completed | Phase 2 | 172 | National Cancer Institute (NCI)NIH | 2 | May 22, 2025 | clinicaltrials |
| NCT04383938 | Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies | completed | Phase 1 / Phase 2 | 40 | Aprea TherapeuticsINDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT05028660 | AURORAX-0093A: Glycosaminoglycan Profiling for Prognostication of Muscle-invasive Bladder Cancer - a Pilot Study(AUR93A) | completed | — | 43 | ElyptaINDUSTRY | 3 | May 9, 2025 | clinicaltrials |
| NCT02439060 | PUBMIC (Prophylactic Use of Biologic Mesh in Ileal Conduit) | completed | N/A | 156 | University of Southern CaliforniaOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT03789682 | CD155 in Bladder Cancer | completed | — | 151 | Fudan UniversityOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT06928220 | The Impact of Manual Versus Mechanical Intestinal Suturing on the Incidence of Postoperative Complications Following Cystectomy With Ileal Conduit(CIMMIS) | completed | N/A | 120 | Fundacio PuigvertOTHER | 1 | Apr 15, 2025 | clinicaltrials |
| NCT03301493 | Genomic Testing and Resulting Medical Decisions | completed | — | 1,500 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06136312 | Clinical Investigation of the Multi4 System | completed | N/A | 18 | Multi4 Medical AbINDUSTRY | 1 | Apr 9, 2025 | clinicaltrials |
| NCT03469362 | Intracorporeal vs Extracorporeal Urinary Diversion After Robot Assisted Radical Cystectomy | completed | N/A | 38 | University of MiamiOTHER | 1 | Mar 25, 2025 | clinicaltrials |
| NCT02365766 | Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects | completed | Phase 1 / Phase 2 | 83 | Jason R. BrownOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT02662309 | Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder(ABACUS) | completed | Phase 2 | 96 | Queen Mary University of LondonOTHER | 4 | Mar 10, 2025 | clinicaltrials |
| NCT05978570 | Physical Therapy in Pre-cystectomy Patients | completed | — | 68 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT02567409 | Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer | completed | Phase 2 | 87 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06851520 | Retrospective Analysis of Different Quadratus Lumborum Block Techniques on Recovery Quality and Analgesic Consumption in Radical Cystectomy Patients(QLB-CYS) | completed | — | 32 | Namik Kemal UniversityOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT00627432 | Gemcitabine With Or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Bladder Cancer | completed | Phase 2 | 44 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT00583349 | Intravesicular Abraxane for Treatment-Refractory Bladder Cancer | completed | Phase 1 / Phase 2 | 46 | Columbia UniversityOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT06818799 | Thulium Laser En-bloc Resection of Primary Non-muscle Invasive Bladder Cancer | completed | N/A | 50 | Helwan UniversityOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT01638533 | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 2 | Feb 7, 2025 | clinicaltrials |
| NCT01489813 | Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment | completed | Phase 2 | 36 | Emory UniversityOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT04492007 | Feasibility Testing of Patient Reported Outcomes - Informed Symptom Management System (PRISMS)(PRISMS) | completed | N/A | 46 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT01697306 | The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer | completed | Phase 2 | 120 | A.O.U. Città della Salute e della ScienzaOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT03473730 | Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer | completed | Early Phase 1 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 30, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Nov 28, 2025source: clinicaltrials